Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Conteltinib - Centaurus Biopharma

Next Previous
Drug Profile

Conteltinib - Centaurus Biopharma

Alternative Names: CT-707; SY-707

Latest Information Update: 21 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Sailin Tai Pharmaceutical; Centaurus Biopharma
  • Developer Beijing Sailin Tai Pharmaceutical; Centaurus Biopharma; Shouyao Holdings
  • Class Antineoplastics; Piperazines; Piperidines; Pyrimidines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion kinase 1 inhibitors; IGF type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 14 May 2025 Shouyao Holdings (Beijing) plans a phase Ib/II trial for Solid tumour (Late-stage disease, Combination-therapy, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet), in June 2025 (NCT06970132)
  • 18 Oct 2022 Phase-III clinical trials in Non-small cell lung cancer in China (unspecified route) (Shouyao Holdings pipeline, October 2022)
  • 18 Oct 2022 Phase-III clinical trials in Pancreatic cancer in China (unspecified route) (Shouyao Holdings pipeline, October 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top